Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2016

01-09-2016 | Original Article

Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery

Authors: Songyang Wu, Hao Liu, Heng Zhang, Chao Lin, Ruochen Li, Yifan Cao, Hongyong He, He Li, Zhenbin Shen, Jing Qin, Jiejie Xu

Published in: Tumor Biology | Issue 9/2016

Login to get access

Abstract

The expression of galectin family has been unraveled in many malignant tumors and related with clinical outcomes. Our current study aims to investigate the prognostic value of galectin-8 expression and refine the current risk stratification system in non-metastatic gastric cancer patients. We retrospectively enrolled 421 patients with gastric cancer from Zhongshan Hospital, Fudan University in 2008. The expression of galectin-8 was detected by immunohistochemistry, and its association with clinicopathological features and prognostic outcomes were assessed. We found that galectin-8 expression was significantly associated with tumor size (P = 0.007), T stage (P = 0.001), N stage (P < 0.001), and tumor node metastasis (TNM) stage (P < 0.001). In addition, low galectin-8 expression indicated poor overall survival (OS) (P < 0.001) and disease-free survival (DFS) (P < 0.001). Furthermore, galectin-8 expression level was identified as an independent favorable prognostic factor for OS (P < 0.001). A predictive nomogram was generated with identified independent prognosticators to evaluate patient OS at 3 and 5 years. Our study suggested that galectin-8 is a potential independent favorable prognostic biomarker for survival and recurrence of patients with gastric cancer after surgical resection and the integration of intratumoral galectin-8 expression level into current TNM staging system would help to refine individual risk stratification.
Literature
1.
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. European J Cancer. 2007;18(2):581–592(12).
2.
3.
Yamashita K, Sakuramoto S, Nemoto M, et al. Trend in gastric cancer: 35 years of surgical experience in Japan. World J Gastroenterol. 2011;17(29):3390–7.CrossRefPubMedPubMedCentral
4.
Jung J, Jung Y, Bang EJ, et al. Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolomic profiling. Ann Surg Oncol. 2014;21(4):736–42.CrossRef
5.
Fengju S, Da Y, Ben L, et al. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res. 2014;20(4):878–89.CrossRef
6.
An H, Xu L, Chang Y, et al. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2015;51(14):1953–61.CrossRefPubMed
7.
Brooks SA, Wilkinson D. Validation of a simple avidin-biotin detection method for Helix pomatia lectin (HPA) binding as a prognostic marker in cancer. Acta Histochem. 2003;105(3):205–12.CrossRefPubMed
8.
9.
Liu F, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci. 2010;1183(1183):158–82.CrossRefPubMed
10.
Ali S, Elliot DE, Emily S, et al. The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression. Exp Mol Pathol. 2014;96(2):212–8.CrossRef
11.
Antongiulio F, Monique T, Ludovic L, et al. Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol. 2002;57(57):813–9.
12.
Hadari YR, Paz K, Dekel R, et al. Galectin-8. A new rat lectin, related to galectin-4. J Biol Chem. 1995;270(7):3447–53.CrossRefPubMed
13.
ZZ S, Lin J, Shen R, et al. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc Natl Acad Sci. 1996;93(14):7252–7.CrossRef
14.
Elola MT, Fátima F, Delgado VM, et al. Expression, localization and function of galectin-8, a tandem-repeat lectin, in human tumors. Histol Histopathol. 2014;29(9):1093–105.PubMed
15.
Troncoso MF, Fátima F, Bacigalupo ML, et al. Galectin-8: a matricellular lectin with key roles in angiogenesis. Glycobiology. 2014;24(10):907–14.CrossRefPubMed
16.
Arun S, Rao PS, Gupta PK, et al. Varied expression and localization of multiple galectins in different cancer cell lines. Oncol Rep. 2008;19(3):587–94.
17.
Hadari YR, Arbel-Goren R, Levy Y, et al. Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis. J Cell Sci. 2000;113(13):2385–97.PubMed
18.
Kim SJ, Shin JY, Lee KD, et al. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One. 2011;6(9):1767–9.
19.
Seok-Jun K, Il-Ju C, Teak-Chin C, et al. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology. 2009;138(3):1035–45.
20.
He XJ, Tao HQ, ZM H, et al. Expression of galectin-1 in carcinoma-associated fibroblasts promotes gastric cancer cell invasion through upregulation of integrin β1. Cancer Sci. 2014;105(11):1402–10.CrossRefPubMedPubMedCentral
21.
Takano J, Morishita A, Fujihara S, et al. Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. Oncol Rep. 2016;35(2):851–60.PubMed
22.
Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.CrossRefPubMed
23.
Zhu XD, Zhang JB, Zhuang PY, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26(16):2707–16.CrossRefPubMed
24.
Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9(2):139–48.CrossRefPubMed
25.
Liu Y, Xu L, Zhu Y, et al. Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma. Urol Oncol. 2015;33(3):112 .e1–8PubMed
26.
Kramer MW, Waalkes S, Serth J, et al. Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder. Urol Int. 2011;87(2):143–50.CrossRefPubMed
27.
Nguyen MC, GH T, Koprivnikar KE, et al. Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy. Cancer Immunol Immunother. 2010;59(9):1313–23.CrossRefPubMed
28.
29.
Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69(1):11–25.CrossRefPubMed
30.
Saito H, Osaki T, Murakami D, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192(3):296–300.CrossRefPubMed
31.
Liu X, Xu Y, Long Z, Zhu H, Wang Y. Prognostic significance of tumor size in T3 gastric cancer. Ann Surg Oncol. 2009;16(7):1875–82.CrossRefPubMed
32.
Zu H, Wang F, Ma Y, Xue Y. Stage-stratified analysis of prognostic significance of tumor size in patients with gastric cancer. PLoS One. 2013;8(1):e54502.CrossRefPubMedPubMedCentral
Metadata
Title
Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery
Authors
Songyang Wu
Hao Liu
Heng Zhang
Chao Lin
Ruochen Li
Yifan Cao
Hongyong He
He Li
Zhenbin Shen
Jing Qin
Jiejie Xu
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5175-y

Other articles of this Issue 9/2016

Tumor Biology 9/2016 Go to the issue

Original Article

Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium

Review

Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells

Original Article

The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults

Original Article

Overexpression of LncRNA-ROR predicts a poor outcome in gallbladder cancer patients and promotes the tumor cells proliferation, migration, and invasion

Review

Role of interleukin-6 in cancer progression and therapeutic resistance

Original Article

Impact of X-linked inhibitor of apoptosis protein on survival of nasopharyngeal carcinoma patients following radiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits